/PRNewswire/ In a press release Friday, Genentech announced approval of Susvimo™, a new advancement in the treatment approach for Wet Age-Related Macular.
/PRNewswire/ In a press release Friday, Genentech announced approval of Susvimo™, a new advancement in the treatment approach for Wet Age-Related Macular.
5/12/2021
The IMT Des Moines Marathon is pleased to announce free digital images presented by Wolfe Eye Clinic for all athletes participating in the races this year.
MarathonFoto, the official event photography provider for the IMT Des Moines Marathon, estimates they will take over 65,000 digital images throughout the race weekend. Athletes will receive multiple high-resolution impressions of their in-person race day accomplishment, thanks to Wolfe Eye Clinic, which allows for downloads and shares across major social media channels.
âGiving back to Iowanâs is such an important part of our core mission at Wolfe Eye Clinic, and a partnership of this magnitude with the IMT Des Moines Marathon was a perfect fit. We are excited to cheer on the participants and provide a complementary way for them to SEE their accomplishment in the days, months, and years that follow,â said Kassandra Trenary, Director of Marketing & Public Relations at Wolfe Eye Clinic.
Share this article
Share this article
WEST DES MOINES, Iowa, Dec. 17, 2020 /PRNewswire/ Wolfe Eye Clinic announced today that Dr. Jared Nielsen, Retina Disease Specialist at Wolfe Eye Clinic was recently the third surgeon in the United States and first in the Midwest to perform surgery in a clinic trial evaluating an investigational gene therapy called GT005 for geographic atrophy secondary to dry age-related macular degeneration.
Dr. Jared Nielsen of Wolfe Eye Clinic exams first patient in clinical trial evaluating an investigational gene therapy for geographic atrophy secondary to dry age-related macular degeneration in November 2020.
Geographic atrophy (GA) is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina, which can lead to loss of visual function over time. There are an estimated 1.4 million Americans affected by GA and there are currently no FDA-approved medicines for this disease.